Skip to content
WeighLab

Evidence review

Ozempic and Alcohol: What Actually Interacts

The short answer

Ozempic's label carries no specific warning about drinking alcohol. Its best-established interaction risk is low blood sugar when it's combined with insulin or a sulfonylurea. On alcohol, the research points the other way: in a trial of 48 adults with alcohol use disorder, semaglutide, the drug in Ozempic, reduced drinks per drinking day and craving versus placebo.

By The WeighLab Bench, Tools & Data Desk
Section index05

For a planned procedure, tell the anesthesia team about treatment and recent symptoms. Our GLP-1 surgery and anesthesia guide explains the individualized approach to preprocedure decisions.

The interaction question people ask about GLP-1s usually goes one of two ways: "is it dangerous to drink on this?" or "will it mess with my other medications?" Both deserve a more precise answer than the internet tends to give, and the actual research points in a less alarming — and more specific — direction than the assumption.

If you also use insulin or a sulfonylurea, our low blood sugar guide covers monitoring and emergency-plan questions to discuss with the prescribing team.

PartnerGrade A

CoreAge Rx

$99/mo sema · $149/mo tirz

Visit CoreAge Rx
Semaglutide
$99/mo
Tirzepatide
$149/mo
Coverage
All 50 states
Brand-name
Compounded only
Modeled / yr
$1,188

CoreAge Rx charges one flat price at every dose, $99 a month for semaglutide and $149 for tirzepatide, with no membership fee.

Read the full CoreAge Rx review →

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never moves the Index. See our disclosure.

Partner

Bodybuilding Health+

74/100
Semaglutide
$179/moMonth-to-month; $159.33 on three months, $158 on six and $141.50 on twelve
Tirzepatide
$209/moMonth-to-month; $179 on three months, $174.67 on six and $187.33 on twelve
Visit Bodybuilding Health+

The mechanism behind every real interaction here

GLP-1 receptor agonists slow gastric emptying — that's the same mechanism responsible for the appetite-suppressing effect and the nausea side effects, and it's also the reason these drugs can change how other things absorb. A systematic review of drug-drug interactions between GLP-1 receptor agonists and oral medications found that co-administration reduced the peak concentration and delayed the time-to-peak of several drug categories — including warfarin, oral contraceptives, acetaminophen, ACE inhibitors, statins and digoxin — consistent with delayed gastric emptying1. The reassuring part: across the studies reviewed, overall drug exposure was not considered clinically significant, and the review concluded dose adjustments are probably not required for most simultaneous use1. That is a more measured finding than "GLP-1s interfere with your other medications" — the absorption timing shifts, but for most of the drugs studied, the total amount absorbed largely does not.

The one interaction that's a real exception

There is a documented exception, and it's specific to the oral tablet — not the injection. Per Wegovy's own prescribing information, a drug-interaction study with the semaglutide tablet found that levothyroxine exposure increased by 33%2 — a genuine, clinically relevant AUC change, not just a delayed peak. Separately, semaglutide injection did not affect the absorption of orally administered medications in the clinical pharmacology trials on record2. If you take levothyroxine and switch from an injectable to an oral semaglutide tablet, that is worth flagging to your prescriber specifically — it is the clearest real interaction in the current label, not a general class effect.

Which drug interaction matters most?

The best-established interaction risk isn't with another oral drug's absorption at all — it's pharmacodynamic. GLP-1s lower blood glucose, and that risk compounds when combined with insulin or an insulin secretagogue such as a sulfonylurea; the label specifically flags increased hypoglycemia risk with that combination and recommends considering a dose reduction of the concomitant insulin or secretagogue when starting a GLP-12. This is the interaction with the clearest real-world consequence, and it is the reason a provider's clinical intake — a scored factor in our methodology — is supposed to ask what else you're taking before you start, not a step to shop past.

Can you drink alcohol on Ozempic?

Start with the label. Ozempic is semaglutide sold for type 2 diabetes, and its prescribing information has no specific warning about drinking alcohol; the only alcohol it mentions is the swab you wipe the injection site with5. The interaction it does flag is the one above: semaglutide taken with insulin or an insulin secretagogue such as a sulfonylurea raises the risk of low blood sugar5. If you drink and also take one of those medicines, that is the combination to raise with your prescriber.

On drinking itself, the common assumption runs backward. Rather than GLP-1s and alcohol being a dangerous mix to avoid, a growing body of research points to GLP-1s reducing alcohol consumption and craving. A randomized, placebo-controlled phase 2 trial in adults with alcohol use disorder found that low-dose semaglutide (up to 1.0 mg weekly — below the standard weight-management maintenance dose) significantly reduced drinks per drinking day and weekly alcohol craving compared with placebo, and predicted greater reductions in heavy drinking over time3. A separate study specifically in individuals with obesity found both semaglutide and tirzepatide were associated with reduced alcohol consumption4. Neither trial is a green light to drink freely — alcohol still carries its own GI and blood-sugar effects that can compound a GLP-1's — and the alcohol-use-disorder trial was small (48 participants) and explicitly framed as evidence justifying larger trials, not a treatment recommendation3. But the documented direction is a reduction in drinking, not a dangerous interaction to fear. That evidence base has moved further since — see can GLP-1s reduce alcohol cravings for a 2026 randomized, placebo-controlled trial specifically in alcohol use disorder and what it adds to the picture.

What this means practically

Tell your provider your full medication list, including anything with a narrow therapeutic window like warfarin, levothyroxine or digoxin, and ask specifically whether your dose of any glucose-lowering medication needs adjusting before you start. If you drink, know that the evidence points toward reduced consumption rather than a specific danger — but that isn't a claim this site is positioned to expand on beyond what the trials report. For what the GI side effects look like on their own, see tirzepatide side effects and semaglutide side effects. The interaction studies behind this are indexed in our research library. Not medical advice — see our medical disclaimer and review your specific medication list and alcohol use with your own clinician.

Frequently asked questions

Do GLP-1s interact with other medications?

GLP-1s delay gastric emptying, which can delay how quickly other oral drugs are absorbed, but a systematic review found overall drug exposure generally wasn't clinically significant for most medications studied. A documented exception is levothyroxine specifically with the oral semaglutide tablet, which increased exposure by 33% in the drug's own label.

Is it dangerous to drink alcohol on a GLP-1?

The evidence points the opposite direction from the common assumption — trials in alcohol use disorder and in obesity both found GLP-1s associated with reduced alcohol consumption and craving, though alcohol still carries its own GI and blood-sugar effects worth discussing with your provider.

What is the most important GLP-1 drug interaction to know about?

Combining a GLP-1 with insulin or a sulfonylurea increases hypoglycemia risk — the label specifically recommends considering a dose reduction of the other medication when starting a GLP-1, which is why a clinician should review your full medication list before you begin.

References

  1. Calvarysky B, Dotan I, Shepshelovich D, et al. (2024). Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety. https://pubmed.ncbi.nlm.nih.gov/38273155/
  2. U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) Prescribing Information — Drug Interactions. DailyMed, U.S. National Library of Medicine. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. Hendershot CS, Bremmer MP, Paladino MB, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/39937469/
  4. Quddos F, Hubshman Z, Tegge A, et al. (2023). Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/38017205/
  5. Novo Nordisk (2026). OZEMPIC (semaglutide) injection — Prescribing Information, Section 7 Drug Interactions and Instructions for Use (label effective June 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.